SCHEMBL3428895

SCHEMBL3428895

O=C(Cn1cc(Nc2ncnc3cc(OCCCN4CCN(CCOP(=O)(O)O)CC4)ccc23)cn1)Nc1cccc(F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 4/20 0.58
FLT3 P36888 3/20 0.58
FLT4 P35916 3/20 0.58
AURKA O14965 12/20 0.55
AURKB Q96GD4 8/20 0.53
KDR P35968 5/20 0.53
EGFR P00533 3/20 0.53
PDGFRA P16234 2/20 0.53
KIT P10721 2/20 0.53
RIPK2 O43353 1/20 0.53
LCK P06239 1/20 0.53
FYN P06241 1/20 0.53
LYN P07948 1/20 0.53
RET P07949 1/20 0.53
HCK P08631 1/20 0.53
CSNK2A2 P19784 1/20 0.53
RAB6A P20340 1/20 0.53
MST1R Q04912 1/20 0.53
MAP2K5 Q13163 1/20 0.53
DYRK1A Q13627 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2052933 0.91 PDGFRB (0.62) PDGFRBFLT3FLT4AURKAAURKB
SCHEMBL6026680 0.90 PDGFRB (0.61) PDGFRBFLT3FLT4AURKAAURKB
SCHEMBL2050779 0.90 CYP3A4 (0.62) PDGFRBFLT3FLT4AURKAAURKB
SCHEMBL2053495 0.89 KDR (0.64) PDGFRBFLT3FLT4AURKAAURKB
SCHEMBL5131787 0.89 PDGFRB (0.59) PDGFRBFLT3FLT4AURKAAURKB
SCHEMBL2049232 0.87 AURKA (0.62) PDGFRBFLT3FLT4AURKAAURKB
SCHEMBL3424557 0.87 AURKA (0.66) PDGFRBFLT3FLT4AURKAAURKB
SCHEMBL2053120 0.85 AURKA (0.70) PDGFRBFLT3FLT4AURKAAURKB
SCHEMBL2049374 0.85 AURKA (0.63) PDGFRBFLT3FLT4AURKAAURKB
SCHEMBL2052351 0.85 AURKA (0.65) PDGFRBFLT3FLT4AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US claimed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP claimed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US claimed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US disclosed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP disclosed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270692-A1 Chemical compounds CCNI, MKI67, TP53 PDGFRB 1544/4885FLT3 703/4885FLT4 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.